AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29533507
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of antibiotics during the previous year
Trial: 29533531
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy for 5 months
Trial: 29533710
Drug: Dietary supplement
RxNorm normalized name: dietary supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplement (Blood Builder®/Iron Response®) containing 26 mg of iron, vitamin C, folate, and other nutrients, taken once daily for 8 weeks.
Trial: 29534721
Drug: CVD 1208S
RxNorm normalized name: Vibrio cholerae CVD 103-HGR strain live antigen Oral Suspension [Vaxchora]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVD 1208S (3 doses, 10 unspecified dosage)
Trial: 29535141
Drug: Worsening renal
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Worsening renal function (WRF) defined as an absolute increase in creatinine of ≥0.3 mg/dL.
Trial: 29535545
Drug: Sofosbuvir plus
RxNorm normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sofosbuvir plus oral weight-based ribavirin for 24 weeks
Trial: 29535712
Drug: TLR4 agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TLR4 agonist glucopyranosyl lipid adjuvant-aqueous formulation (GLA-AF) with CN54gp140 vaccine, administered intramuscularly three times at 1-month intervals.
Trial: 29536342
Drug: Patient-Centered Methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-Centered Methadone Treatment (PCM)
Trial: 29536342
Drug: Typical Treatment
RxNorm normalized name: Atypical neutrophil cytoplasmic antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Typical Treatment Sessions
Trial: 29537444
Drug: 0.3% adapalene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3% adapalene and 2.5% benzoyl peroxide gel plus oral doxycycline 100 mg twice daily
Trial: 29537906
Drug: Postoperative concurrent
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative concurrent chemoradiotherapy (CRT), n = 153
Trial: 29540222
Drug: Apheresis treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apheresis treatment
Trial: 29540225
Drug: Weekly iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly iron and/or folic acid supplementation
Trial: 29540225
Drug: Trial provision
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trial provision of free treatment
Trial: 29540234
Drug: Polycap DS®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polycap DS® (containing aspirin 100 mg, atenolol 50 mg, ramipril 5 mg, thiazide 12.5 mg, simvastatin 20 mg) taken as two capsules once daily for 12 months
Trial: 29540234
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (UC) with separate, individual secondary preventive medications prescribed at the physician's discretion
Trial: 29540603
Drug: Weekly docetaxel,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly docetaxel, cisplatin, and cetuximab (TPC)
Trial: 29541969
Drug: Sustained ventricular
RxNorm normalized name: DRESSING,VENTRICULAR ASSIST DEVICE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained ventricular tachyarrhythmia event with appropriate ICD therapy.
Trial: 29541969
Drug: All-cause death
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All-cause death without preceding sustained ventricular tachyarrhythmia with appropriate ICD therapy.
Trial: 29542886
Drug: ICS/LABA combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICS/LABA combined therapy
Trial: 29543932
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg intravenously every 3 weeks until disease progression or unacceptable toxic effects
Trial: 29544445
Drug: Trastuzumab (Herceptin®)
RxNorm normalized name: trastuzumab Injection [Herceptin]
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab (Herceptin®) therapy
Trial: 29544454
Drug: Niclosamide 2
RxNorm normalized name: niclosamide 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niclosamide 2 g orally once a day until disease progression or toxicity
Trial: 29545095
Drug: Durvalumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab (10 mg/kg) every 2 weeks for up to 12 months
Trial: 29545772
Drug: Degarelix (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Degarelix (0.5 ml bolus injection)
Trial: 29545951
Drug: Botox injections
RxNorm normalized name: Botox
DrugBank: DaxibotulinumtoxinA (DB17929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botox injections in HFS patients
Trial: 29545951
Drug: Healthy volunteers
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy volunteers without Botox injections
Trial: 29545953
Drug: Selective retina
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective retina therapy (SRT) with real-time feedback-controlled dosimetry
Trial: 29546247
Drug: Twice-weekly in-person
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly in-person and telephone-based guidance on calorie-restricted diets and aerobic exercise
Trial: 29548561
Drug: Three-dimensional conformal
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-dimensional conformal radiation therapy (3-DCRT)
Trial: 29548934
Drug: 1.8 mg
RxNorm normalized name: menthol 1.8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8 mg liraglutide once daily
Trial: 29548934
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg glimepiride together with 1 g metformin twice daily
Trial: 29549175
Drug: Abatacept (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abatacept (10 mg/kg, expansion cohort)
Trial: 29549175
Drug: Abatacept (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abatacept (all doses)
Trial: 29549598
Drug: Adapalene 0.3%
RxNorm normalized name: ADAPALENE 0.3% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapalene 0.3% gel, applied once daily for the first 4 weeks and twice daily for the following 20 weeks.
Trial: 29550382
Drug: Voxtalisib 50
RxNorm normalized name: Voxtalisib
DrugBank: Voxtalisib (DB12400)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voxtalisib 50 mg orally twice daily in 28-day continuous dosing cycles until progression or unacceptable toxicity
Trial: 29550382
Drug: Voxtalisib 50
RxNorm normalized name: Voxtalisib
DrugBank: Voxtalisib (DB12400)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voxtalisib 50 mg orally twice daily
Trial: 29551225
Drug: Flubio® (Influenza
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flubio® (Influenza HA Trivalent) vaccine, administered in 1 or 2 doses with a 28-day interval.
Trial: 29551225
Drug: Flubio® (Influenza
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flubio® (Influenza HA Trivalent) vaccine
Trial: 29551338
Drug: Sirolimus (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirolimus (2 mg per day, adjusted to maintain a therapeutic range of 6-15 ng/mL) for 12 months
Trial: 29551401
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 25-s time delay and $0.25 discount
Trial: 29551401
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 25-s time delay and $0.25 tax
Trial: 29551775
Drug: Ilorasertib 40-340
RxNorm normalized name: Ilorasertib
DrugBank: Ilorasertib (DB11694)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ilorasertib 40-340 mg orally twice daily (Arm II)
Trial: 29551775
Drug: Ilorasertib 10-180
RxNorm normalized name: Ilorasertib
DrugBank: Ilorasertib (DB11694)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ilorasertib 10-180 mg orally once daily (Arm I)
Trial: 29551775
Drug: Ilorasertib 8-32
RxNorm normalized name: Ilorasertib
DrugBank: Ilorasertib (DB11694)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ilorasertib 8-32 mg intravenously once daily (Arm III)
Trial: 29552014
Drug: Intralesional (IL)
RxNorm normalized name: Ile
DrugBank: Isoleucine (DB00167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intralesional (IL) treatment with ipilimumab
Trial: 29552321
Drug: Vemurafenib 960
RxNorm normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vemurafenib 960 mg twice daily plus fotemustine 100 mg/m2 intravenously every three weeks
Trial: 29552321
Drug: Vemurafenib 960
RxNorm normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vemurafenib 960 mg twice daily plus fotemustine
Trial: 29552356
Drug: Prolonged-release fampridine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged-release fampridine (PRF) 10 mg BID
Trial: 29556418
Drug: Sarilumab 200
RxNorm normalized name: SARILUMAB 200MG/1.14ML INJ SYR 1.14ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarilumab 200 mg every 2 weeks plus csDMARDs
Trial: 29558281
Drug: Veliparib with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veliparib with concurrent radiotherapy (RT) to the chest wall and regional lymph nodes (50 Gy plus a 10-Gy boost)
Trial: 29560743
Drug: Liletta (levonorgestrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liletta (levonorgestrel 52 mg IUS)
Trial: 29561066
Drug: IdeS (imlifidase)
RxNorm normalized name: IDE-CEL
DrugBank: Imlifidase (DB15258)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: IdeS (imlifidase) 0.12 mg/kg body weight ×2
Trial: 29561066
Drug: IdeS (imlifidase)
RxNorm normalized name: IDE-CEL
DrugBank: Imlifidase (DB15258)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: IdeS (imlifidase) 0.25 mg/kg ×1
Trial: 29561066
Drug: IdeS (imlifidase)
RxNorm normalized name: IDE-CEL
DrugBank: Imlifidase (DB15258)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: IdeS (imlifidase) 0.25 mg/kg ×2
Trial: 29561219
Drug: Acute reperfusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute reperfusion therapies including thrombectomy and thrombolysis in the acute phase
Trial: 29561296
Drug: Talimogene laherparepvec
RxNorm normalized name: Talimogene laherparepvec
DrugBank: Talimogene laherparepvec (DB13896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Talimogene laherparepvec (≤4 ml 10 PFU/ml; administered on day 1 and every 2 weeks thereafter)
Trial: 29562855
Drug: RectroNectin-activated cytokine-induced
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RectroNectin-activated cytokine-induced killer (R-CIK) cell immunotherapy
Trial: 29563871
Drug: Naltrexone and
RxNorm normalized name: Naltrexone and Bupropion Hydrochlorides Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone and Bupropion combination treatment
Trial: 29564045
Drug: Prolonged-release oxycodone/naloxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged-release oxycodone/naloxone at a starting dose of 10/5 mg/day (maximum 80/40 mg/day) for 8 weeks
Trial: 29564045
Drug: Prolonged-release oxycodone/naloxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged-release oxycodone/naloxone
Trial: 29565424
Drug: 4,000 L rhGAA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4,000 L rhGAA
Trial: 29566106
Drug: Avelumab, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avelumab, 10 mg/kg, by 1-hour intravenous infusion every 2 weeks until disease progression or unacceptable toxic effects.
Trial: 29566186
Drug: Red and
RxNorm normalized name: ferric oxide (red and/or yellow)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red and processed meat intake (10 g/d)
Trial: 29566186
Drug: Cereal intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cereal intake (50 g/d)
Trial: 29566186
Drug: Dietary fiber
RxNorm normalized name: Dietary Fiber 1.67 GM Oral Tablet, Chewable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary fiber intake (10 g/d)
Trial: 29566190
Drug: Protein intake
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein intake from dairy products (per 5 g/d)
Trial: 29566190
Drug: Protein intake
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein intake from meat and fish (per 2 g/d)
Trial: 29566246
Drug: Glecaprevir/pibrentasvir (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glecaprevir/pibrentasvir (300 mg/120 mg) for 8 weeks in noncirrhotic patients and 12 weeks in cirrhotic patients.
Trial: 29566656
Drug: blended cognitive
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: blended cognitive behavioral therapy (b-CBT) consisting of three face-to-face sessions and eight online sessions
Trial: 29566698
Drug: Oral health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral health intervention program from infancy to age 5 years.
Trial: 29566762
Drug: CyberKnife accelerated
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CyberKnife accelerated partial breast irradiation (CK-APBI) with 30 Gy in five fractions, treatment time approximately 60 min (range 35 to 120 min).
Trial: 29567071
Drug: Adjuvant fluorouracil-based
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adjuvant fluorouracil-based chemotherapy after D2 gastrectomy (n=193)
Trial: 29567071
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy plus surgery (n=323)
Trial: 29567774
Drug: Lenalidomide, dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide, dosage and duration not available
Trial: 29568374
Drug: Folate receptor-targeted
RxNorm normalized name: folate
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folate receptor-targeted intraoperative molecular imaging (FR-IMI) with OTL38
Trial: 29569246
Drug: 3T3-J2 feeder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3T3-J2 feeder cell culture with Y-27632 (ROCK inhibitor) in conditional reprograming conditions (CRC)
Trial: 29570971
Drug: CYP2D6 and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYP2D6 and fluoxetine
Trial: 29570971
Drug: CYP2C19 and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYP2C19 and sertraline
Trial: 29570971
Drug: CYP2B6 and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYP2B6 and sertraline
Trial: 29571854
Drug: Glatiramer acetate
RxNorm normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glatiramer acetate 40 mg three times a week
Trial: 29571854
Drug: Glatiramer acetate
RxNorm normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glatiramer acetate 20 mg daily
Trial: 29571946
Drug: Nilotinib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nilotinib (400 mg twice per day)
Trial: 29572391
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of donor-derived CD8
Trial: 29572709
Drug: Pasireotide LAR
RxNorm normalized name: pasireotide LAR 20 MG Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasireotide LAR 60 mg/m for at least 6 months
Trial: 29572709
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with everolimus 10 mg/d
Trial: 29573889
Drug: Broccoli sprouts
RxNorm normalized name: broccoli sprout extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broccoli sprouts (30 g/day) for 10 weeks
Trial: 29574070
Drug: Pitavastatin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pitavastatin (4 mg/d)
Trial: 29574465
Drug: Oral HIV
RxNorm normalized name: HIV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral HIV test
Trial: 29574497
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with CKD (albuminuria ≥ 30 mg/day)
Trial: 29574497
Drug: Patients aged
RxNorm normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients aged ≥ 75 years with albuminuria < 10 mg/day
Trial: 29574622
Drug: 7.5 mg/week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg/week MTX + adalimumab
Trial: 29574622
Drug: 20 mg/week
RxNorm normalized name: selinexor 60 mg twice weekly (120 mg/week) (20 mg x 6) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/week MTX + adalimumab
Trial: 29576341
Drug: Human bone
RxNorm normalized name: Allogeneic human bone marrow-derived mpc
DrugBank: Rexlemestrocel-L (DB17606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human bone marrow-derived stem cells (BMDSCs) infusion
Trial: 29576341
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of BMDSCs and their CD133+ fraction
Trial: 29578248
Drug: Bupivacaine dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine dosage
Trial: 29578250
Drug: Vasopressin infusion
RxNorm normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vasopressin infusion 4.8 U/h
Trial: 29578250
Drug: Vasopressin infusion
RxNorm normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vasopressin infusion combined with nitroglycerin infusion
Trial: 29578646
Drug: Lamotrigine 25
RxNorm normalized name: lamotrigine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamotrigine 25 to 100 mg once daily
Trial: 29579214
Drug: Temocillin 1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temocillin 1, 2 or 3 g (total of 61 doses)
Trial: 29579214
Drug: New temocillin
RxNorm normalized name: temocillin
DrugBank: Temocillin (DB12343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New temocillin dosage regimen (not specified in detail)
Trial: 29579214
Drug: Currently licensed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Currently licensed dosage regimen
Trial: 29584546
Drug: Nivolumab 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 3 mg/kg every 2 weeks until disease progression/unacceptable toxicity
Trial: 29587672
Drug: Antidepressant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant treatment initiation
Trial: 29587672
Drug: Switching antidepressants
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switching antidepressants
Trial: 29587677
Drug: OTS-GC-A24 cancer
RxNorm normalized name: OT-730
DrugBank: OT-730 (DB16112)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OTS-GC-A24 cancer vaccine at 1 mg administered in 3-weekly (3w), 2-weekly (2w), and weekly (1w) cohorts.
Trial: 29587759
Drug: Regular pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular pain medication intake
Trial: 29587807
Drug: Group-based Acceptance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-based Acceptance and Commitment Therapy (ACT)
Trial: 29587808
Drug: SRP in
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SRP in combination with 400 mg MTZ + 500 mg AMX, starting at the first SRP session (active phase group)
Trial: 29587808
Drug: SRP in
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SRP in combination with 400 mg MTZ + 500 mg AMX, starting after 3 months of its completion (healing phase group)
Trial: 29588304
Drug: Very low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Very low-dose rivaroxaban added to DAPT (ASA + clopidogrel or ASA + ticagrelor)
Trial: 29590008
Drug: Chemotherapy (investigator's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (investigator's choice, e.g., docetaxel 75 mg/m2)
Trial: 29590311
Drug: Primaquine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primaquine 0.5 mg/kg/day for 14 days
Trial: 29590325
Drug: Low alcohol
RxNorm normalized name: Low alcohol beer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low alcohol detection threshold (BrAC = 0.025 mg/l, BACSwe = 0.05‰ or US = 0.0053g/dl)
Trial: 29590401
Drug: Intravenous injections
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injections of (S,S)-[11C]O-methylreboxetine ([11C]MRB) during hypoglycemia
Trial: 29592869
Drug: Monthly $60-per-child
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly $60-per-child benefit
Trial: 29592869
Drug: Monthly $30-per-child
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly $30-per-child benefit
Trial: 29592876
Drug: Third-party fecal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third-party fecal microbiota transplantation (FMT) capsules administered no later than 4 weeks after neutrophil engraftment.
Trial: 29593099
Drug: Pilaralisib tablets
RxNorm normalized name: Pilaralisib
DrugBank: Pilaralisib (DB11772)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pilaralisib tablets (400 mg once daily)